WO2006105338A3 - Fc VARIANTS WITH OPTIMIZED PROPERTIES - Google Patents

Fc VARIANTS WITH OPTIMIZED PROPERTIES Download PDF

Info

Publication number
WO2006105338A3
WO2006105338A3 PCT/US2006/011752 US2006011752W WO2006105338A3 WO 2006105338 A3 WO2006105338 A3 WO 2006105338A3 US 2006011752 W US2006011752 W US 2006011752W WO 2006105338 A3 WO2006105338 A3 WO 2006105338A3
Authority
WO
Grant status
Application
Patent type
Prior art keywords
fc variants
optimized properties
fc
optimized
properties
Prior art date
Application number
PCT/US2006/011752
Other languages
French (fr)
Other versions
WO2006105338A2 (en )
Inventor
Gregory Alan Lazar
Wei Dang
John R Desjarlais
Sher Bahadur Karki
Original Assignee
Xencor Inc
Gregory Alan Lazar
Wei Dang
John R Desjarlais
Sher Bahadur Karki
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734Complement-dependent cytotoxicity [CDC]

Abstract

The present invention relates to Fc variants with optimized properties, methods for their generation, Fc polypeptides comprising Fc variants with optimized properties, and methods for using Fc variants with optimized properties.
PCT/US2006/011752 2002-09-27 2006-03-31 Fc VARIANTS WITH OPTIMIZED PROPERTIES WO2006105338A3 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
US66719705 true 2005-03-31 2005-03-31
US60/667,197 2005-03-31
US11/124,620 2005-05-05
US11124620 US8188231B2 (en) 2002-09-27 2005-05-05 Optimized FC variants
US70537805 true 2005-08-03 2005-08-03
US60/705,378 2005-08-03
US72329405 true 2005-10-03 2005-10-03
US72333505 true 2005-10-03 2005-10-03
US60/723,335 2005-10-03
US60/723,294 2005-10-03

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CA 2602663 CA2602663A1 (en) 2005-03-31 2006-03-31 Fc variants with optimized properties
AU2006230413A AU2006230413B8 (en) 2005-03-31 2006-03-31 Fc variants with optimized properties
EP20060748967 EP1871808A2 (en) 2005-03-31 2006-03-31 Fc VARIANTS WITH OPTIMIZED PROPERTIES
JP2008504389A JP2008537941A (en) 2005-03-31 2006-03-31 Fc variants with optimized properties
IL18614507A IL186145D0 (en) 2005-03-31 2007-09-20 Fc VARIANTS WITH OPTIMIZED PROPERTIES

Publications (2)

Publication Number Publication Date
WO2006105338A2 true WO2006105338A2 (en) 2006-10-05
WO2006105338A3 true true WO2006105338A3 (en) 2007-03-29

Family

ID=37054149

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/011752 WO2006105338A3 (en) 2002-09-27 2006-03-31 Fc VARIANTS WITH OPTIMIZED PROPERTIES

Country Status (3)

Country Link
EP (1) EP1871808A2 (en)
CA (1) CA2602663A1 (en)
WO (1) WO2006105338A3 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158760B2 (en) 2000-10-06 2012-04-17 Kyowa Hakko Kirin Co., Ltd Glycoengineered, recombinant antibody
US8852586B2 (en) 2004-11-12 2014-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2275541T3 (en) 1999-04-09 2016-05-09 Kyowa Hakko Kirin Co Ltd A method for controlling the activity of immunologically functional molecule.
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
DK1931709T3 (en) 2005-10-03 2017-03-13 Xencor Inc Fc variants with optimized Fc receptor binding properties
ES2426817T3 (en) 2004-08-04 2013-10-25 Mentrik Biotech, Llc Fc variants regions
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
WO2008121160A3 (en) * 2006-11-21 2009-01-22 Xencor Inc Optimized antibodies that target cd5
WO2008091798A3 (en) * 2007-01-22 2008-10-02 Xencor Inc Optimized ca9 antibodies and methods of using the same
CA2669412A1 (en) * 2007-01-23 2008-07-31 Xencor, Inc. Optimized cd40 antibodies and methods of using the same
ES2538990T3 (en) 2007-01-24 2015-06-25 Kyowa Hakko Kirin Co., Ltd. Composition genetically recombinant antibody having enhanced effector activity
WO2008092117A3 (en) * 2007-01-25 2008-12-31 Xencor Inc Immunoglobulins with modifications in the fcr binding region
WO2008098115A3 (en) * 2007-02-07 2008-10-02 Xencor Inc Optimized igf-1r antibodies and methods of using the same
JP2010526868A (en) 2007-05-14 2010-08-05 ノビミューン エスアー Fc receptor binding polypeptide having altered effector function
EP3392273A1 (en) * 2007-05-30 2018-10-24 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
KR20100057021A (en) * 2007-08-01 2010-05-28 글락소 그룹 리미티드 Novel antibodies
CN106519025A (en) 2007-09-26 2017-03-22 中外制药株式会社 Method of Modifying Isoelectric Point of Antibody Via Amino Acid Substitution in CDR
DK2708559T3 (en) 2008-04-11 2018-06-14 Chugai Pharmaceutical Co Ltd Antigen-binding molecule which is capable of repeated bonding two or more antigen molecules
WO2009129538A3 (en) * 2008-04-18 2010-07-01 Xencor, Inc. Human equivalent monoclonal antibodies engineered from nonhuman variable regions
US8455249B2 (en) 2009-05-01 2013-06-04 The University Of Tokyo Highly effective anti-cadherin antibody for induction of antibody-dependent cellular cytotoxicity in vivo
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
US8362210B2 (en) 2010-01-19 2013-01-29 Xencor, Inc. Antibody variants with enhanced complement activity
CN102933231B (en) 2010-02-10 2015-07-29 伊缪诺金公司 Cd20 antibody and uses thereof
WO2011104604A3 (en) 2010-02-23 2011-12-01 Glenmark Pharmaceuticals S.A. Anti-alpha2 integrin antibodies and their uses
JP5820800B2 (en) 2010-03-02 2015-11-24 協和発酵キリン株式会社 Modified antibody compositions
EP2698431A4 (en) 2011-03-30 2014-10-01 Chugai Pharmaceutical Co Ltd Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity
WO2012032080A1 (en) 2010-09-07 2012-03-15 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H Stabilised human fc
RU2013115927A (en) 2010-09-10 2014-10-20 Апексиджен, Инк. Anti-IL-1β and method of administration
US20140234340A1 (en) 2010-11-30 2014-08-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
US20140335089A1 (en) 2011-09-30 2014-11-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for promoting elimination of antigens
EP2681243B1 (en) 2011-03-03 2018-09-05 Apexigen, Inc. Anti-il-6 receptor antibodies and methods of use
WO2012122513A3 (en) 2011-03-10 2012-12-27 Omeros Corporation Generation of anti-fn14 monoclonal antibodies by ex-vivo accelerated antibody evolution
CN103635488B (en) 2011-04-29 2016-12-14 埃派斯进有限公司 Antibodies and methods of using the anti--cd40
JP6284766B2 (en) 2011-09-30 2018-02-28 中外製薬株式会社 Ion concentration-dependent binding molecule library
JP6352634B2 (en) 2011-09-30 2018-07-04 中外製薬株式会社 Antigen-binding molecules that induce an immune response against a target antigen
WO2013047748A1 (en) 2011-09-30 2013-04-04 中外製薬株式会社 Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
WO2013087789A1 (en) * 2011-12-13 2013-06-20 Glykos Finland Ltd. Antibody isoform arrays and methods thereof
WO2013093809A1 (en) 2011-12-23 2013-06-27 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
EP2832856A4 (en) 2012-03-29 2016-01-27 Chugai Pharmaceutical Co Ltd Anti-lamp5 antibody and utilization thereof
WO2013180201A1 (en) 2012-05-30 2013-12-05 中外製薬株式会社 Antigen-binding molecule for eliminating aggregated antigens
CN107964042A (en) 2012-05-30 2018-04-27 中外制药株式会社 Target-tissue-specific antigen-binding molecule
CN105517571A (en) 2013-06-24 2016-04-20 中外制药株式会社 Therapeutic agent comprising humanized anti-epiregulin antibody as active ingredient for non-small-cell lung carcinoma excluding adenocarcinoma
EP3050896A4 (en) 2013-09-27 2017-08-09 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
CA2930307A1 (en) 2013-11-13 2015-05-21 Zymeworks Inc. Monovalent antigen binding constructs targeting egfr and/or her2 and uses thereof
WO2015083764A1 (en) 2013-12-04 2015-06-11 中外製薬株式会社 Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules
WO2015109212A1 (en) 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
EP3204425A2 (en) 2014-10-09 2017-08-16 Genzyme Corporation Glycoengineered antibody drug conjugates
KR20180054923A (en) 2014-12-19 2018-05-24 추가이 세이야쿠 가부시키가이샤 Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
KR20170110129A (en) 2015-02-05 2017-10-10 추가이 세이야쿠 가부시키가이샤 Ion concentration-dependent antibody comprising an antigen binding domain, Fc domain variants dogs, antibody binding to IL-8, and their use
WO2017010874A1 (en) 2015-07-10 2017-01-19 Merus N.V. Human cd3 binding antibody
KR20180064541A (en) 2015-10-23 2018-06-14 화이자 인코포레이티드 Wherein -il-2 antibodies, and compositions and the use thereof
WO2018045379A1 (en) 2016-09-02 2018-03-08 Dana-Farber Cancer Institute, Inc. Composition and methods of treating b cell disorders

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999051642A1 (en) * 1998-04-02 1999-10-14 Genentech, Inc. Antibody variants and fragments thereof
WO2000042072A2 (en) * 1999-01-15 2000-07-20 Genentech, Inc. Polypeptide variants with altered effector function
US20020004587A1 (en) * 2000-04-11 2002-01-10 Genentech, Inc. Multivalent antibodies and uses therefor
WO2004029207A2 (en) * 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
WO2004063351A2 (en) * 2003-01-09 2004-07-29 Macrogenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
WO2004099249A2 (en) * 2003-05-02 2004-11-18 Xencor, Inc. Optimized fc variants and methods for their generation
WO2005056759A2 (en) * 2003-12-04 2005-06-23 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
WO2005056606A2 (en) * 2003-12-03 2005-06-23 Xencor, Inc Optimized antibodies that target the epidermal growth factor receptor
WO2005070963A1 (en) * 2004-01-12 2005-08-04 Applied Molecular Evolution, Inc Fc region variants
WO2005092925A2 (en) * 2004-03-24 2005-10-06 Xencor, Inc. Immunoglobulin variants outside the fc region
WO2006019447A1 (en) * 2004-07-15 2006-02-23 Xencor, Inc. Optimized fc variants
WO2006047350A2 (en) * 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
WO2006053301A2 (en) * 2004-11-12 2006-05-18 Xencor, Inc. Fc variants with altered binding to fcrn
WO2006085967A2 (en) * 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999051642A1 (en) * 1998-04-02 1999-10-14 Genentech, Inc. Antibody variants and fragments thereof
WO2000042072A2 (en) * 1999-01-15 2000-07-20 Genentech, Inc. Polypeptide variants with altered effector function
US20020004587A1 (en) * 2000-04-11 2002-01-10 Genentech, Inc. Multivalent antibodies and uses therefor
WO2004029207A2 (en) * 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
WO2004063351A2 (en) * 2003-01-09 2004-07-29 Macrogenics, Inc. IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
WO2004099249A2 (en) * 2003-05-02 2004-11-18 Xencor, Inc. Optimized fc variants and methods for their generation
WO2005056606A2 (en) * 2003-12-03 2005-06-23 Xencor, Inc Optimized antibodies that target the epidermal growth factor receptor
WO2005056759A2 (en) * 2003-12-04 2005-06-23 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
WO2005070963A1 (en) * 2004-01-12 2005-08-04 Applied Molecular Evolution, Inc Fc region variants
WO2005092925A2 (en) * 2004-03-24 2005-10-06 Xencor, Inc. Immunoglobulin variants outside the fc region
WO2006085967A2 (en) * 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
WO2006019447A1 (en) * 2004-07-15 2006-02-23 Xencor, Inc. Optimized fc variants
WO2006047350A2 (en) * 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
WO2006053301A2 (en) * 2004-11-12 2006-05-18 Xencor, Inc. Fc variants with altered binding to fcrn

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. 104, no. 11, Part 1, November 2004 (2004-11-01), 46TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; SAN DIEGO, CA, USA; DECEMBER 04 -07, 2004, pages 394A, ISSN: 0006-4971 *
CHAPPEL M S ET AL: "Identification of a secondary FcyRI binding site within a genetically engineered human IgG antibody", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 268, no. 33, 1993, pages 25124 - 25131, XP002337952, ISSN: 0021-9258 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; November 2004 (2004-11-01), LAZAR GREG ET AL: "Improving the efficacy of rituxan by rational protein engineering.", XP002403709, Database accession no. PREV200510269378 *
LAZAR GREG A ET AL: "Engineered antibody Fc variants with enhanced effector function", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 103, no. 11, March 2006 (2006-03-01), pages 4005 - 4010, XP002403708, ISSN: 0027-8424 *
See also references of EP1871808A2 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158760B2 (en) 2000-10-06 2012-04-17 Kyowa Hakko Kirin Co., Ltd Glycoengineered, recombinant antibody
US8852586B2 (en) 2004-11-12 2014-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
US8883973B2 (en) 2004-11-12 2014-11-11 Xencor, Inc. Fc variants with altered binding to FcRn
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn

Also Published As

Publication number Publication date Type
EP1871808A2 (en) 2008-01-02 application
CA2602663A1 (en) 2006-10-05 application
WO2006105338A2 (en) 2006-10-05 application

Similar Documents

Publication Publication Date Title
WO2004029207A3 (en) Optimized fc variants and methods for their generation
WO2004099249A3 (en) Optimized fc variants and methods for their generation
WO2008121767A3 (en) Stitched polypeptides
WO2006083936A3 (en) Anti-ephb2 antibodies and methods using same
WO2008121563A3 (en) Modified fgf-21 polypeptides and their uses
WO2007067313A3 (en) Ion sources, systems and methods
WO2008070269A3 (en) Methods, software and systems for imaging
환경부 비점오염원 설치신고 업무처리지침
Deshpande Osmanabad jilhyatil proudh shikshan samsayecha chikitsakh abhyas
Kambale Adivasi varliche loksahitya
전자 et al. 목 차
WO2007106915A8 (en) Antibodies to egfl7 and methods for their use
CA2595826A1 (en) Composites and methods for the manufacture and use thereof
WO2010051056A3 (en) ANTI-FcεRI POLYPEPTIDES AND THEIR USES
WO2009100102A3 (en) Ts23 alpha-amylase variants with altered properties
GB0505596D0 (en) Process, compounds and their uses

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 1452/MUMNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 186145

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2006230413

Country of ref document: AU

ENP Entry into the national phase in:

Ref document number: 2602663

Country of ref document: CA

ENP Entry into the national phase in:

Ref document number: 2008504389

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase in:

Ref country code: DE

ENP Entry into the national phase in:

Ref document number: 2006230413

Country of ref document: AU

Date of ref document: 20060330

Kind code of ref document: A

NENP Non-entry into the national phase in:

Ref country code: RU

121 Ep: the epo has been informed by wipo that ep was designated in this application